Health Effects of Ultra-processed Food Intake (UPFront)
Health Effects of Ultra-processed Food Intake: a Randomized Crossover Feeding Study
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Linnea Bärebring, PhD, Associate professor
- Telefonnummer: +46 0317863771
- E-mail: linnea.barebring@gu.se
Undersøgelse Kontakt Backup
- Navn: Therese Karlsson, PhD, Associate professor
- E-mail: therese.karlsson@gu.se
Studiesteder
-
-
-
Gothenburg, Sverige, 40530
- Rekruttering
- University of Gothenburg
-
Kontakt:
- Linnea Bärebring, PhD, Associate professor
- Telefonnummer: +46 0317863771
- E-mail: linnea.barebring@gu.se
-
Kontakt:
- Therese Karlsson, PhD, Associate professor
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Age 20-60 years
- Weight stable (less than 5% weight change in the past 3 months)
- No plans to change weight
- Willing to eat the study diet and a mixed diet
- Habitually eats breakfast, lunch and dinner
- Has provided informed consent to participate in the study
Exclusion Criteria:
- Allergy or intolerance to foods included in the study. Participants with lactose intolerance treated with lactase may participate if they take enzymes.
- BMI <18.5 or >35 kg/m²
- >8h/week of intense physical activity
- Use of medications known to significantly affect appetite (e.g., oral corticosteroids, antipsychotic medications, or GLP-1 receptor agonists)
- Use of lipid-lowering medications (e.g., statins or PCSK9 inhibitors)
- Diagnosed diabetes or capillary blood glucose at or above 12.2 mmol/L
- Disease associated with malabsorption (e.g., inflammatory bowel disease or celiac disease)
- Previous bariatric surgery
- Established cardiovascular disease (heart failure, myocardial infarction, or stroke) or cancer
- Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study
- Deemed likely to have poor adherence
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Sequence 1: high UPF, low UPF
Diet high in UPF, followed by a diet low in UPF
|
Diet high in Ultra-processed food (>80 % of total energy intake)
Diet low in Ultra-processed food (<20 % of total energy intake)
|
|
Eksperimentel: Sequence 2: low UPF, high UPF
Diet low in UPF, followed by a diet high in UPF
|
Diet high in Ultra-processed food (>80 % of total energy intake)
Diet low in Ultra-processed food (<20 % of total energy intake)
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Leptin
Tidsramme: Change from baseline to 6 weeks
|
Change from baseline to 6 weeks
|
|
|
ApoB
Tidsramme: Change from baseline to 6 weeks
|
Apolipoprotein B
|
Change from baseline to 6 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Leptin
Tidsramme: Change from baseline to 2 weeks
|
Change from baseline to 2 weeks
|
|
|
ApoB
Tidsramme: Change from baseline to 2 weeks
|
Apolipoprotein B
|
Change from baseline to 2 weeks
|
|
Ghrelin, PYY, cholecystokinin, insulin
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
Other appetite-regulating hormones
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
|
Blood lipid profile
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
ApoA1, LDL, HDL, VLDL, total cholesterol, triglycerides, Lp(a)
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
|
Body weight
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
|
|
Body composition
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
Fat mass and fat-free mass
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
|
Blood pressure
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
Diastolic and systolic blood pressure
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
|
Biomarkers of ultra-processed food intake
Tidsramme: At 2 weeks and at 6 weeks
|
Measured in blood and urine
|
At 2 weeks and at 6 weeks
|
|
Gut microbiome
Tidsramme: At 2 weeks and 6 weeks
|
Change in gut microbial composition and diversity (alpha- and beta)
|
At 2 weeks and 6 weeks
|
|
Glucose
Tidsramme: Continuous during the first 2 weeks
|
Glucose, measured by continuous blood glucose monitoring
|
Continuous during the first 2 weeks
|
|
Energy intake
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
Ad libitum energy intake at standardized test meal
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
|
Food cravings and eating behavior
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
Control of Eating Questionnaire, Three Factor Eating Questionnaire, Power of Food Scale
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
|
Subjective appetite
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
Self-rated appetite before and after a standardized test meal
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Oral microbiome
Tidsramme: At 2 weeks and 6 weeks
|
Change in oral microbial composition
|
At 2 weeks and 6 weeks
|
|
Compliance
Tidsramme: At 2 weeks and 6 weeks
|
Compliance assessed by food records
|
At 2 weeks and 6 weeks
|
|
Sleep
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
Pittsburgh Sleep Quality Index
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
|
Well-being
Tidsramme: Change from baseline to 2 weeks and from baseline to 6 weeks
|
WHO-5 Wellbeing Index
|
Change from baseline to 2 weeks and from baseline to 6 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Linnea Bärebring, PhD, Associate professor, Göteborg University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2025-08976-01
- 2025 (U.S. NIH-bevilling/kontrakt: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .